What Bipolar Medications Are Safe During Pregnancy?

No single bipolar medication is perfectly “safe” during pregnancy, but several carry reassuringly low risks and are widely used when the benefits of mood stability outweigh the small chance of harm. Lamotrigine and certain second-generation antipsychotics top most clinicians’ lists, while lithium remains an option at lower doses with appropriate monitoring. The medications clearly flagged as dangerous are valproate (Depakote) and, to a lesser extent, carbamazepine (Tegretol). What makes this question difficult is that untreated bipolar disorder itself threatens both you and your baby, so the real decision is rarely “medication versus no medication” but rather “which medication, at what dose, with what monitoring.”

Why Stopping All Medication Can Be Risky

It is tempting to think the safest approach is to go off everything during pregnancy. For some people with milder illness who have been stable for a long time, that can work. A systematic review found that a subset of pregnant women remain stable without mood stabilizers, but another group with more severe or unstable bipolar disorder benefits from continued prophylactic medication during pregnancy and postpartum to prevent relapse.¹ The trouble is that bipolar relapse during pregnancy is not just unpleasant. It exposes both you and your baby to real physical harm.

Bipolar disorder itself is linked to higher rates of gestational hypertension, hemorrhage, cesarean delivery, and smaller-than-expected babies.² Depression episodes raise cortisol and stress-hormone levels, which can reduce blood flow to the placenta and affect fetal growth.³ Stopping effective treatment also puts you at risk for manic or depressive episodes that can disrupt prenatal care, sleep, nutrition, and your ability to function during a physically demanding time.⁴ The conversation with your prescriber should weigh these harms against the specific risks of whatever medication you are taking, not simply compare “medication” against an imagined risk-free baseline.

Medications to Avoid

Valproate (sold as Depakote, Depakene, or valproic acid) is the clearest “no” in pregnancy. It is a potent teratogen with well-documented risks of neural tube defects, heart malformations, and limb abnormalities. Beyond structural birth defects, children exposed to valproate in utero face roughly a threefold increased risk of autism spectrum disorder, with an absolute risk around 4.4% compared with about 2.4% in unexposed children of mothers with epilepsy.⁵ Every major guideline agrees that valproate should be avoided during pregnancy whenever possible, and many clinicians now recommend switching people of childbearing potential off valproate well before conception.

Carbamazepine (Tegretol) is less dangerous than valproate but still raises red flags. A meta-analysis of over 1,200 exposed pregnancies found increased rates of congenital anomalies, particularly neural tube defects, cardiovascular defects, urinary tract anomalies, and cleft palate.⁶ A large case-control study confirmed that spina bifida risk was roughly two and a half to four times higher with carbamazepine, though the risks for cleft lip and some other malformations were not meaningfully increased.⁷ Carbamazepine is not as strongly contraindicated as valproate, but when safer alternatives exist, most guidelines recommend switching.

Lamotrigine as a First-Line Option

Lamotrigine (Lamictal) has the strongest safety record among mood stabilizers used in bipolar disorder. A systematic review and meta-analysis found that first-trimester exposure to lamotrigine was not associated with significantly increased rates of birth defects compared with either healthy controls or disease-matched controls, and rates of miscarriage, stillbirth, preterm delivery, and small-for-gestational-age babies were not elevated.⁸ That same analysis found lamotrigine was statistically significantly less teratogenic than valproate. A separate large study confirmed no dose-response relationship with major birth defects, meaning even higher doses did not appear to raise the risk.⁹

Lamotrigine is FDA-approved for bipolar maintenance (preventing mood episodes) rather than for acute mania, so it works best for people whose primary concern is keeping depressive and mixed episodes at bay. If mania is the bigger risk, your doctor may pair lamotrigine with a low-risk antipsychotic or consider lithium instead.

Lithium During Pregnancy

Lithium’s reputation as a pregnancy hazard is decades old and partly outdated. In the 1970s, voluntary case registries suggested an enormous risk of Ebstein’s anomaly, a rare heart defect, and the relative risk was estimated at 400 times baseline. Later controlled studies showed that figure was wildly inflated.¹⁰ The most rigorous modern data comes from a large cohort study that found cardiac malformations in about 2.4% of lithium-exposed infants compared with 1.15% of unexposed infants. The increased risk was real but modest, and it was dose-dependent: daily doses of 600 mg or less showed no statistically significant increase, while doses above 900 mg roughly tripled the cardiac malformation risk.¹¹

This means lithium is not off the table during pregnancy, but the approach matters. Using the lowest effective dose, especially during the first trimester when the heart is forming, significantly reduces the risk. A detailed fetal echocardiogram around weeks 18 to 22 can screen for Ebstein’s anomaly and other cardiac defects. For people with severe bipolar disorder who respond uniquely well to lithium and have not done well on alternatives, continuing it at a carefully managed dose is a reasonable choice.

Second-Generation Antipsychotics

Atypical (second-generation) antipsychotics are increasingly used in bipolar disorder for both acute mania and maintenance, and the pregnancy data on them has grown substantially. A multinational cohort study of over 26,000 antipsychotic-exposed pregnancies found that prenatal exposure to individual antipsychotics was generally not associated with an increase in major congenital malformations. The overall malformation rate among atypical-antipsychotic-exposed pregnancies was about 4.3%, compared with around 3% in the general population, but much of that gap narrowed after accounting for other maternal factors.¹²

Looking at individual drugs, olanzapine and quetiapine have the most reassuring data. A systematic review of first-trimester exposures found malformation rates of about 3.5% for olanzapine and 3.6% for quetiapine, with relative risks near 1.0, meaning essentially no increase over baseline.¹³ Risperidone is the one atypical antipsychotic that has raised a small flag. One large study found a modest increase in overall malformations with risperidone that persisted after adjusting for confounders.¹⁴ The absolute risk is still low, but if you are stable on risperidone and planning a pregnancy, it is worth discussing whether quetiapine or olanzapine might be a reasonable switch.

One caveat with antipsychotics, especially olanzapine and clozapine, is metabolic effects. A Swedish register study found that women taking higher-risk second-generation antipsychotics during pregnancy had increased rates of gestational diabetes, and their infants were more likely to be large for gestational age.¹⁵ This is not a structural birth defect but a metabolic complication that requires monitoring. Blood sugar screening becomes especially important if you are taking olanzapine or clozapine during pregnancy.

Drug Levels Change During Pregnancy

Pregnancy alters how your body processes medications, and failing to account for this is one of the most common reasons women relapse during pregnancy even while still technically “on” their medication. Lithium clearance increases by 30 to 50% during pregnancy because blood volume and kidney filtration rates rise dramatically. Plasma levels drop, and the risk of relapse climbs, especially in the third trimester. Then at delivery, blood volume plummets and lithium levels spike back up quickly, creating a brief window of potential toxicity.¹⁶

Lamotrigine is even more dramatically affected. Its clearance can increase by more than 330% between preconception and the third trimester, and on average women with epilepsy need a dose increase of about 250% to maintain therapeutic levels.¹⁶ After delivery, the clearance drops rapidly and levels can rebound, increasing the risk of side effects or toxicity if the dose is not tapered back down within days to weeks postpartum.¹⁷ Regular blood-level monitoring throughout pregnancy and especially around delivery is not optional for either lithium or lamotrigine; it is the main tool that keeps these drugs both effective and safe.

What Happens to the Baby After Delivery

Even when a medication does not cause structural birth defects, exposure in late pregnancy can produce temporary symptoms in the newborn. For lithium, case reports describe what is sometimes called “floppy infant syndrome,” with lethargy, poor sucking, low muscle tone, and occasionally respiratory distress or thyroid changes in the first days of life. The large majority of these symptoms resolve on their own, and most babies make a full recovery.¹⁸ A Belgian hospital analysis noted that mild to moderate neonatal symptoms should be anticipated with late-pregnancy lithium exposure and planned for with appropriate monitoring.¹⁹

Antipsychotics can also cause neonatal adaptation issues. A national register study found elevated relative risks for withdrawal symptoms, neurological irritability, and persistent pulmonary hypertension in exposed newborns, though the absolute risks were low: about 1 to 2% for each outcome.²⁰ The risk of neonatal withdrawal symptoms increases when the mother is taking three or more neuropsychiatric medications at once.²¹ Symptoms can include feeding difficulties, tremors, irritability, abnormal muscle tone, and persistent crying, typically appearing within the first hours to weeks after delivery.²² These effects are almost always temporary, but your delivery team should know what you are taking so they can monitor your baby appropriately.

Long-Term Developmental Outcomes in Children

Beyond birth defects and neonatal symptoms, parents understandably worry about whether prenatal medication exposure affects their child’s brain development years down the line. The news here is largely reassuring for the medications typically recommended in pregnancy.

For antipsychotics, a study of school-aged children who had been exposed in utero found no association between prenatal antipsychotic exposure and IQ or performance on a battery of tests measuring attention, memory, affect recognition, language, and motor skills.²³ A large multinational cohort study similarly found no increased risk of neurodevelopmental disorders or poor academic performance after adjusting for confounders.²⁴ A national birth cohort study found that the raw twofold increase in neurodevelopmental disorders associated with antipsychotic exposure was almost entirely explained by other maternal factors rather than the drugs themselves, though aripiprazole showed a possible small residual signal that needs further study.²⁵

For lamotrigine, a systematic review and meta-analysis concluded that prenatal exposure was not associated with neurodevelopmental disorders overall, language delay, autism, or ADHD. There was a possible signal for psychomotor delay in children under three, but this was based on very small studies with significant limitations and was not seen in older age groups.²⁶ For lithium, the limited data available have not identified adverse neurodevelopmental outcomes.²⁷ Valproate remains the outlier, with consistently elevated neurodevelopmental risks that extend well beyond structural birth defects.

Benzodiazepines and Other Adjuncts

Many people with bipolar disorder also take a benzodiazepine (like lorazepam or clonazepam) for anxiety or sleep, and the question of whether to continue these during pregnancy comes up frequently. Older reports raised alarm about cleft palate and other malformations, but more recent data is less concerning. A pregnancy registry study found major malformations in about 3.2% of benzodiazepine-exposed infants, essentially the same rate as the unexposed comparison group, suggesting benzodiazepines do not have major teratogenic effects.²⁸ That said, benzodiazepine use late in pregnancy can contribute to neonatal sedation and withdrawal symptoms, so the lowest possible dose for the shortest duration is the standard approach.

Breastfeeding on Bipolar Medications

The postpartum period is the highest-risk window for bipolar relapse, so continuing or reinstating medication after delivery is often critical. Lithium has preliminary evidence supporting its role in preventing postpartum psychosis, a psychiatric emergency that affects roughly 1 in 1,000 deliveries but is far more common in bipolar disorder.²⁹

Whether you can breastfeed while taking bipolar medications depends on the specific drug. Lithium passes into breast milk, but infant serum levels tend to be about half the breast milk level and roughly a fifth of the mother’s blood level. A study monitoring nursing infants found low lithium levels that were well tolerated, with no significant adverse clinical or behavioral effects, though minor and transient lab changes were occasionally noted.³⁰ Close monitoring of the infant is recommended, including periodic blood work and attention to hydration, but breastfeeding on lithium is no longer considered automatically inadvisable.

Lamotrigine does reach higher concentrations in neonatal serum compared with some other mood stabilizers, but few adverse events have been reported. Clinicians recommend watching for drowsiness, poor feeding, and apnea, particularly in the first month.³¹ Among the atypical antipsychotics, olanzapine and quetiapine appear to transfer minimally into breast milk. Olanzapine was undetectable in nearly all infant serum samples studied, and quetiapine was not detected in breast milk at maternal doses of 75 mg or lower. Risperidone transfers at relatively higher levels, though no adverse events have been reported. Aripiprazole data are limited, and it has been linked to decreased prolactin levels that may impair milk supply.³¹

Electroconvulsive Therapy as an Alternative

When medication options are too risky or have failed, electroconvulsive therapy (ECT) is sometimes used during pregnancy for severe bipolar depression or mania. A population-based study found that the response rate to ECT in pregnant women was similar to non-pregnant matched controls (about 74% versus 65%), and rates of ECT-related adverse events were comparable. There were no preterm births or severe pregnancy complications directly attributable to the treatment.³² A review of multiple systematic reviews found that four out of five concluded ECT administration during pregnancy was relatively safe, while one recommended it only as a last resort.³³ ECT avoids the issue of continuous fetal drug exposure entirely, which makes it an attractive option for people who are severely ill and cannot tolerate or do not respond to the safer medications.

When the Father Takes Valproate

An emerging and somewhat surprising area of research concerns paternal medication exposure around the time of conception. A cohort study of children in Denmark, Norway, and Sweden found that paternal valproate use within three months before conception was associated with a higher risk of neurodevelopmental disorders in offspring compared with paternal use of lamotrigine or levetiracetam.³⁴ However, a larger population-based analysis using sibling comparisons found no increased risk of autism, ADHD, tic disorders, intellectual disability, or congenital malformations associated with paternal valproate exposure.³⁵ The evidence is mixed and still early. What is clear is that the risk from maternal valproate exposure is well-established and orders of magnitude more important than any theoretical paternal effect. But this area is worth watching as new data emerge.

Where Guidelines Agree and Disagree

A review of international evidence-based guidelines found moderate agreement on some points: most guidelines caution against valproate, carbamazepine, and (to a lesser degree) lithium during the perinatal period. But there was less agreement about the safety of lamotrigine and antipsychotics, and particularly little consensus on breastfeeding recommendations.³⁶ This inconsistency reflects the fundamental challenge: the strongest evidence comes from observational studies and registries rather than randomized trials (since nobody is going to randomize pregnant women to potentially harmful drugs), and different expert panels weigh the same imperfect data differently.

In practice, this means your prescriber’s individual experience and your own illness history matter a great deal. A woman with a history of severe manic psychosis has a different risk calculus than someone whose bipolar disorder has always been mild and primarily depressive. The conversation should be specific to your situation, ideally starting before conception so medication switches and dose adjustments can happen before the highest-risk first trimester. If you are already pregnant and on a medication you are worried about, do not stop abruptly. Abrupt discontinuation can trigger rebound episodes, and any dose changes should be done in coordination with your treatment team.